Huifeng Pharmaceutical

Beijing Heyuan Huifeng Pharmaceutical Technology Co., Ltd. (headquartered at Hefei Keying Pharmaceutical Technology Co., Ltd.) is a CRO company providing innovative clinical trial technology services to the global pharmaceutical and medical device industries. The company has always been committed to accelerating innovation, greatly improving clinical R&D efficiency and shortening the time to market for pharmaceutical products through precise insight, innovative strategies and operational excellence. The company adheres to a strategy of specialization and regionalization, and has carried out in-depth work in innovative new pharmaceutical products such as innovative small-molecule chemical drugs, antibody drugs, innovative traditional Chinese medicines and natural drugs, recombinant biologics, cell and gene therapies, etc., and has accumulated rich experience and resources in fields such as hematology, allergy, endocrinology, oncology, immunology, and rare diseases. The company has cooperated with more than 600 clinical institutions and has had more than 200 products approved for marketing. It has more than 20 offices in Beijing, Shanghai, Guangzhou, Hefei, Kunming, Chongqing, Taiyuan, Shenyang, Shijiazhuang, Nanjing, Tianjin, Jinan, Qingdao, Changsha, etc., and based on the company's strategic development plan, officially established the Suzhou Branch of Hefei Keying Pharmaceutical Technology Co., Ltd. in Suzhou in early 2023. After more than ten years of development, the company has a sound quality management system, a professional and stable operations team and complete SOPs, strictly follows China GCP and works with reference to ICH-GCP, and its business scope includes Phase I to IV clinical trials of drugs and medical devices. Since 2015, when General Secretary Xi Jinping's important instructions on the "Four Strictest" (i.e., the "722 Storm") were implemented, more than 20 clinical inspections have been passed, with a pass rate of 100%.